Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network

Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3–5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituxim...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: KENKRE, VAISHALEE P., LONG, WALTER L., EICKHOFF, JENS C., BLANK, JULES H., McFARLAND, THOMAS A., BOTTNER, WAYNE, REZAZEDEH, HAMIED, WERNDLI, JAE E., BAILEY, HOWARD H., KAHL, BRAD S.
Format: Artigo
Sprog:Inglês
Udgivet: 2011
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3489168/
https://ncbi.nlm.nih.gov/pubmed/21864042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2011.580404
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker